Clinical Trials on Endometrial Cancers With FGFR2 Mutations in India
Total 8 results
-
DyAnsys, Inc.RecruitingCancer of Cervix | Cancer of EndometriumIndia
-
Tata Memorial CentreRecruitingCervical Cancer | Endometrial CancerIndia
-
Tata Memorial HospitalRecruitingNon-small Cell Lung Cancer | Oligometastatic Disease | Driver MutationIndia
-
Queensland Centre for Gynaecological CancerThe University of QueenslandRecruitingSurgery | Sentinel Lymph Node | Endometrial Cancer Stage IAustralia, United States, Brazil, Singapore, India
-
Tata Memorial HospitalRecruitingAsymptomatic Brain Metastases | Driver Mutation Positive Non-small Cell Lung CancerIndia
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
CytRxTerminatedStage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural EffusionUnited States, Mexico, India, Ukraine, Bulgaria, Russian Federation